Standard BioTools Inc. has officially completed the sale of its Microfluidics business to ARCHIMED, a global private equity firm specializing in healthcare. This significant transaction, announced on November 3, 2026, allows Standard BioTools to focus on its core operations while providing ARCHIMED with a robust addition to its portfolio in the pharmaceutical preparations sector.

The Microfluidics business will now operate under the name Biomark Scientific, positioning itself as a leader in accessible and scalable genomic workflows powered by proprietary microfluidics technology. This strategic move is expected to enhance the capabilities of ARCHIMED in the rapidly evolving field of genomic profiling.

Background

Standard BioTools Inc., incorporated in Delaware, operates within the pharmaceutical preparations industry (SIC 2834). The company is publicly traded on the Nasdaq under the ticker symbol LAB. Recent filings indicate a proactive approach to restructuring and optimizing its business operations, including the sale of its Microfluidics business.

What the Filing Says

According to the SEC filing (accession number 0001140361-26-041705), Standard BioTools announced the completion of the sale of its Microfluidics business to ARCHIMED. The filing states, "On November 3, 2026, Standard BioTools Inc. issued a joint press release with ARCHIMED, announcing the closing of Standard BioTools’ previously announced sale of its Microfluidics business to ARCHIMED." This transition marks a new chapter for the Microfluidics business, which will now be known as Biomark Scientific.

Impact

This acquisition is likely to affect various stakeholders, including employees of the Microfluidics business, customers relying on its products, and competitors in the genomic profiling market. The transition to Biomark Scientific may also influence the competitive landscape, particularly for companies focused on microfluidics technology and genomic workflows.

What's Next

The filing does not specify what happens next regarding further developments or future filings related to this transaction. However, the establishment of Biomark Scientific under ARCHIMED is expected to lead to new innovations in genomic profiling technology.